Menu

Italian Scientist’s Retraction Count Hits 15

Alfredo Fusco, a once prominent cancer researcher, has been under investigation for alleged research misconduct since 2012.

Mar 5, 2018
Diana Kwon

ISTOCK, DNY59

Update (March 6): An independent review into how the Ohio State University (OSU) handled misconduct allegations regarding one of its scientists, Carlo Croce, agreed that the institution “reached reasoned and supportable conclusions” and that several of the concerns “did not rise to the level of a cognizable allegation of research misconduct.” According to Retraction Watch, although this review was focused on Croce, this was not the first time that OSU has had to have a decision examined. After a 2013 investigation by The Columbus Dispatch, the university was asked to re-investigate pharmacology professor Terry Elton, who was ultimately found to be guilty of misconduct. 

Five of Italian cancer researcher Alfredo Fusco’s papers, published between 1985 and 2001, were retracted last week, Retraction Watch reports.

Fusco, a once a prominent investigator at the University of Naples, has been under investigation by public prosecutors since 2012. According to a 2017 piece in Nature, the allegations of research misconduct against him include using fraudulent data to win grants and hiring a photographer to manipulate scientific images for publication.

“We have not intentionally manipulated any publication,” Fusco, who has denied all allegations, told Nature in 2017. He also noted that any image manipulations were “mistakes,” and stated, “I was not aware of it, since I do not participate in the assembling of the figures.”

Four of the recently retracted papers were published in the Molecular and Cellular Biology, and one in the Journal of Virology, both journals belonging to the American Society for Microbiology. Identical retraction notices appeared on all five articles, which stated, in part: “Questions have been raised by concerned readers about the integrity of the data. The American Society for Microbiology has reviewed the figures and confirmed evidence of apparent manipulation and duplication.” It also notes that the studies’ authors did not agree to the retractions. 

One of these papers was coauthored by Carlo Croce, a cancer researcher at Ohio State University who has also faced allegations of misconduct. This was Croce’s eighth retraction. Retraction Watch notes that despite the charges against him, Croce recently received several prestigious awards, including the $300,000 Dan David Prize in February.

According to Retraction Watch, Croce has filed lawsuits against The New York Times and Purdue University professor David Sanders, claiming a March 2017 piece in the newspaper about investigations into wrongdoing defamed him.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!